Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atengood
- Development stage
- Unknown
- Lead developer
- GoodMed Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Atengood is a branded generic version of atenolol, developed and marketed by GoodMed Healthcare. It is a selective beta-1 adrenergic receptor blocker used primarily for the management of hypertension and angina pectoris. By selectively antagonizing beta-1 receptors in the heart, it reduces heart rate, cardiac output, and myocardial oxygen demand, thereby lowering blood pressure and preventing anginal symptoms. It is administered orally as tablets and is part of GoodMed Healthcare's cardiovascular product portfolio in markets such as Kenya.
- Brand names
- AtengoodAtengood 50Atengood50Atengood-50Atengood 100Atengood100Atengood-100
- Other names
- atenolol
02
Targets
ADRB1 (β1)
Beyond the preview
Go deeper on Atengood.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atengood.